NVCR - CIK 0001645113
NovoCure Ltd (NVCR) reported net income of -$136.23M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$136.23M | +19.4% |
| FY 2024 | -$169.00M | +18.4% |
| FY 2023 | -$207.00M | -122.6% |
| FY 2022 | -$93.00M | -60.3% |
| FY 2021 | -$58.00M | -392.8% |
| FY 2020 | $19.81M | +374.0% |
| FY 2019 | -$7.23M | +88.6% |
| FY 2018 | -$63.56M | -3.1% |
| FY 2017 |
NovoCure Ltd (NVCR) reported net income of -$136.23M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, NovoCure Ltd's net income declined from -$77.37M to -$136.23M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$61.66M |
| +53.2% |
| FY 2016 | -$131.84M | -18.2% |
| FY 2015 | -$111.58M | -38.3% |
| FY 2014 | -$80.68M | -4.3% |
| FY 2013 | -$77.37M | - |